Delta9-tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: a critical examination of the preclinical literature
2015 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6519, Vol. 97, no 6, 587-596 p.Article in journal (Refereed) Published
An Internet search with search words "cannabis cures cancer" produce a wealth of sites claiming that cannabis has this effect. These sites are freely accessible to the general public and thus contribute to public opinion. But do delta9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) cure cancer? In the absence of clinical data other than a safety study and case reports, preclinical data should be evaluated in terms of its predictive value. Using a strict approach where only concentrations and/or models relevant to the clinical situation are considered, the current preclinical data do not yet provide robust evidence that systemically administered Δ9-THC will be useful for the curative treatment of cancer. There is more support for an intratumoral route of administration of higher doses of Δ9-THC. CBD produces effects in relevant concentrations and models, although more data are needed concerning its use in conjunction with other treatment strategies.
Place, publisher, year, edition, pages
Wiley-Blackwell, 2015. Vol. 97, no 6, 587-596 p.
Pharmacology and Toxicology
IdentifiersURN: urn:nbn:se:umu:diva-105244DOI: 10.1002/cpt.84ISI: 000355131400016PubMedID: 25669486OAI: oai:DiVA.org:umu-105244DiVA: diva2:825955